PFE — PFIZER INC catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

14 verified catalyst event(s) for PFIZER INC (ticker PFE). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2026-11-12 — A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Hav · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-11-12 in 8d ESTIMATED	READOUT A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop Phase 2 · Atopic Dermatitis	PFE PFIZER INC	PF-07275315, PF-07264660	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-29 in 25d ESTIMATED	READOUT A Study to Learn About the Study Medicine Called Rimegepant in Women When Used f Phase 3 · Menstrual Migraine	PFE PFIZER INC	Rimegepant, Rimegepant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-02 in 28d ESTIMATED	READOUT A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 t Phase 3 · Severe Alopecia Areata	PFE PFIZER INC	Ritlecitinib higher dose, Ritlecitinib l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-04 in 30d ESTIMATED	READOUT A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth D Phase 3 · Lyme Disease	PFE PFIZER INC	VLA15	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-08 in 1mo ESTIMATED	READOUT A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults Phase 2 · Hidradenitis Suppurativa	PFE PFIZER INC	Ritlecitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-25 in 2mo ESTIMATED	READOUT A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spont Phase 2 · Chronic Spontaneous Urticaria	PFE PFIZER INC	Ritlecitinib 50 mg, Ritlecitinib 100 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-30 in 2mo ESTIMATED	READOUT Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in Phase 3 · Breast Cancer	PFE PFIZER INC	Vepdegestrant (ARV-471/PF-07850327), Pal	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-31 in 2mo ESTIMATED	READOUT PF-07104091 as a Single Agent and in Combination Therapy Phase 2 · Small Cell Lung Cancer, Ovarian Cancer	PFE PFIZER INC	PF-07104091 monotherapy dose escalation,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-31 in 2mo ESTIMATED	READOUT Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Ave Phase 3 · Advanced Malignancies, NSCLC	PFE PFIZER INC	Avelumab, Lorlatanib, Talazoparib, Pemet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-18 in 3mo ESTIMATED	READOUT Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. Phase 3 · Lower Respiratory Tract Illness	PFE PFIZER INC	RSVpreF	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-25 in 3mo ESTIMATED	READOUT A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF Phase 3 · Respiratory Syncytial Virus (RSV)	PFE PFIZER INC	RSVpreF	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-26 in 4mo ESTIMATED	READOUT A Study to Learn About the Study Medicine (Called PF-07220060 in Combination Wit Phase 1/2 · Breast Cancer, Solid Tumors	PFE PFIZER INC	PF-07220060 + PF-07104091 combination do	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-28 in 4mo ESTIMATED	READOUT A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevromet Phase 3 · Metastatic Castrate Resistant Prostate Cancer (mCRPC)	PFE PFIZER INC	PF-06821497, Docetaxel, Enzalutamide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-03-08 in 4mo ESTIMATED	READOUT A Study to Learn About the Study Medicine Called PF-07275315 in People With Mode Phase 2 · Asthma	PFE PFIZER INC	PF-07275315	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change